Decision by Nice to rule out drug being available on the NHS comes despite health watchdog MHRA giving green light
The UK’s health regulator has rejected a drug that can slow the progression of Alzheimer’s disease, saying its benefits were too small to justify the costs of the therapy and close monitoring of patients for signs of “serious side-effects”.
Lecanemab, which is given twice a month, removes sticky clumps of protein amyloid beta from the brain, believed to be a hallmark of the disease. The drug is not a cure. But in clinical trials, the therapy slowed cognitive decline by 27% in early Alzheimer’s patients, compared with a placebo.
